Linda Mileshkin
Linda Mileshkin
Peter MacCallum Cancer Centre
Verified email at petermac.org
TitleCited byYear
Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England Journal of Medicine 365 (14), 1273-1283, 2011
18252011
Whole–genome characterization of chemoresistant ovarian cancer
AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ...
Nature 521 (7553), 489, 2015
5872015
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
2792017
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring
L Mileshkin, R Stark, B Day, JF Seymour, JB Zeldis, HM Prince
Journal of Clinical Oncology 24 (27), 4507-4514, 2006
2102006
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
JR Infante, DR Camidge, LR Mileshkin, EX Chen, RJ Hicks, D Rischin, ...
Journal of Clinical Oncology 30 (13), 1527-1533, 2012
1472012
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
L Mileshkin, JJ Biagi, P Mitchell, C Underhill, A Grigg, R Bell, ...
Blood 102 (1), 69-77, 2003
1352003
Cervical cancer: a global health crisis
W Small Jr, MA Bacon, A Bajaj, LT Chuang, BJ Fisher, MM Harkenrider, ...
Cancer 123 (13), 2404-2412, 2017
1322017
Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening?
E Beardsley, M Jefford, L Mileshkin
Journal of Clinical Oncology 25 (9), e13-e14, 2007
1282007
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ...
Modern pathology 28 (6), 836, 2015
1242015
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
S Moran, A Martínez-Cardús, S Sayols, E Musulén, C Balañá, ...
The Lancet Oncology 17 (10), 1386-1395, 2016
1222016
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non–small cell lung cancer treated with erlotinib
L Mileshkin, RJ Hicks, BGM Hughes, PLR Mitchell, V Charu, BJ Gitlitz, ...
Clinical Cancer Research 17 (10), 3304-3315, 2011
1062011
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre …
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The lancet oncology 19 (3), 295-309, 2018
832018
Low physical activity levels and functional decline in individuals with lung cancer
CL Granger, CF McDonald, L Irving, RA Clark, K Gough, A Murnane, ...
Lung Cancer 83 (2), 292-299, 2014
782014
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre …
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The Lancet Oncology 17 (8), 1114-1126, 2016
722016
A comparison of fluorine‐18 fluoro‐deoxyglucose PET and technetium‐99m sestamibi in assessing patients with multiple myeloma
L Mileshkin, R Blum, JF Seymour, A Patrikeos, RJ Hicks, HM Prince
European journal of haematology 72 (1), 32-37, 2004
692004
An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a …
LJ Worth, MJ Dooley, JF Seymour, L Mileshkin, MA Slavin, KA Thursky
British journal of cancer 92 (5), 867, 2005
662005
Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
RW Tothill, J Li, L Mileshkin, K Doig, T Siganakis, P Cowin, A Fellowes, ...
The Journal of pathology 231 (4), 413-423, 2013
622013
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer
D Etemadmoghadam, G Au-Yeung, M Wall, C Mitchell, M Kansara, ...
Clinical Cancer Research 19 (21), 5960-5971, 2013
592013
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
HM Prince, L Mileshkin, A Roberts, V Ganju, C Underhill, J Catalano, ...
Clinical Cancer Research 11 (15), 5504-5514, 2005
592005
Lung cancer: challenges and solutions for supportive care intervention research
P Schofield, A Ugalde, M Carey, L Mileshkin, M Duffy, D Ball, S Aranda
Palliative & supportive care 6 (3), 281-287, 2008
572008
The system can't perform the operation now. Try again later.
Articles 1–20